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Incidence and clinical importance of perioperative histamine
release: randomised study of volume loading and antihistamines
after induction of anaesthesia
Summary
Although histamine release is recognised as a common event
during anaesthesia and surgery, few clinicians judge the
resultant cardiorespiratory disturbances serious enough to
warrant prophylaxis with antihistamines. We have assessed
the incidence and importance of histamine release in a
randomised 2 &times; 2 factorial study.
240 patients representing a routine throughput of major
general surgery were studied during a standardised induction
of anaesthesia and preoperative loading of the circulation with
either Ringer solution or Haemaccel-35, with or without
antihistamine prophylaxis with dimetindene (H1) plus
cimetidine (H2). Cardiorespiratory disturbances were graded
as detectable, clinically relevant, or life-threatening from
observers’ records of the anaesthesia and the actions taken by
the anaesthetists. Disturbances that were accompanied by
significant rises in plasma histamine were further designated
histamine-related, and those that were not were designated
histamine-unrelated. Anaesthetists, observers, and
designators were blinded to whether or not the patients had
received antihistamines and to which solution was used for
circulatory volume loading.
Clinically relevant or life-threatening histamine-related
disturbances occurred in 8% of the patients who after
induction of anaesthesia received Ringer without
antihistamines, in 26% of those who received Haemaccel
without antihistamines, and in 2% or less of those who received
antihistamines (p&prcue;0 0001). There were 4 life-threatening
histamine-related disturbances, all in patients who received
Haemaccel without antihistamines (p<0 01). Histamine-
unrelated disturbances occurred in 16% overall, with no
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obvious effect of Haemaccel or antihistamines. The histamine-
related disturbances under anaesthesia were remarkable for
their severity (even with small rises in histamine
concentrations), for the prevalence of bradycardia, and for the
absence of skin signs. Their likelihood and severity were
increased in patients with tumours.
The results of the trial make a case for routine prophylaxis
with antihistamines as part of anaesthetic management.
Lancet 1994; 343: 933-40
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Introduction
Clinicians recognise that histamine is released quite
commonly during anaesthesia and surgery, 1-4 and
occasionally has ill-effects. However, when some alarming
and life-threatening complication develops during a routine
procedure, they will seldom blame histamine.s Moreover,
the usual view is that such events are too rare to warrant
either routine or selective use of antihistamine as
prophylaxis6-despite documentation of incidences of
histamine-related disturbances of up to 30%/ some of them
very severe.8
The classic requirements9 for establishing that a putative
mediator substance is responsible for an observed
disturbance are (i) that the disturbance is brought about by
giving the substance, (ii) that the substance is released when
the disturbance occurs naturally, and (iii) that a specific
antagonist of the substance prevents the disturbance from
occurring. 10 As early as 1929, histamine was noted to imitate
features of the untoward events seen during anaesthesia,
surgery, trauma and sepsis;" and other such substances
include serotonin, various kinins, eicosanoids, cytokines,
and nitric oxide. However, the classic tests for implicating
putative mediators have still not been applied to histamine
in a routine clinical setting, despite the availability of the
means to do so-namely, reliable and sensitive assays,12
powerful and specific antagonists of the actions of
histamine on two of its most important receptors (H1 and
H2) in the cardiovascular and respiratory systems,13 and the
methodology of the controlled clinical trial,14
We have completed a randomised double-blind
controlled clinical trial of the effects of prophylaxis against
possible effects of histamine release during anaesthesia,
surgery, and the subsequent 30 days in a representative
sample of patients undergoing routine major general
surgery under standardised but typical general anaesthesia.
Dimetindene maleate was used to block the effects of
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Total elective operations Dec 1988-Sept 1991 4230
First 2 patients In the 3 operating theatres each weekday 3339
Patients excluded by escape criteria
Holidays on weekdays 244
Failure of measurement capabilities 351
Anaesthetist’s errors in applying exclusion rules 88
Anaesthetist’s preference for "personal" induction 111
Patient not from general surgery clinic 44
Absence of written consent by patient 157
Private patients (excluded by surgeon) 548
Emergency cases interrupting 25
No general anaesthetic 178
Not 1st operation during study period 22
Age less than 18 yr 13
Peptic G) tract disease with H, antagonist 328
Transplantation/bypass 1
ASA class > 3 131
Allergy or asthma 259
Patients specifically eligible for study 839
Study sample selected randomly 240
Table 1: Eligibility of study patients from clinic population
histamine at Hi receptors and cimetidine the effects at H2
receptors .7 This report is restricted to results obtained
between the induction of anaesthesia and the start of
surgery. During this time the patients received circulatory
volume loading either with Ringer solution, which releases
virtually no histamine,15 or with Haemaccel-35, with which
histamine release is thought to be appreciable but
modest&mdash;comparable with that induced by many other
drugs used in anaesthesia and surgery.l-4
Methods ’
The study was approved by the institutional review board in
Marburg and Mainz after extensive published discussion of its
intended methods17,18 and a pilot study of its feasibility. Only the
main features of the methods are described below.
The defined population from which the sample was selected
comprised the 4230 patients who underwent elective abdominal,
oncological, endocrine, vascular, or thoracic surgery in three
operating theatres in Mainz between December, 1988, and
October, 1991. The inclusion and exclusion criteria listed in table 1
and the algorithm for selecting patients were specified and
published in advance.17 By a random number allocation from 1 to 6
to the patients of each day, the first sample of 3339 was reduced to
839, and the patient with the lowest remaining random number in
the nominal block of 6 was selected as the one patient for the next
morning for operation until 240 had been recruited. This sample
size was designed to provide a power of 0-8 at a significance level of
2cx=0’05 to detect a reduction of 30% in the primary endpoint
variable-histamine-related cardiorespiratory disturbance.
The 240 patients were allocated randomly to four treatment
groups of 60 patients each, for a double-blind 2 x 2 factorial study
of the effects of antihistamine (anti-H1Hz) prophylaxis and volume
loading with Haemaccel. The four treatment groups were placebo-
Ringer, placebo-Haemaccel, antihistamines-Ringer, and
antihistamines-Haemaccel. The treatments were prepared by
personnel otherwise uninvolved with the study, and were
administered to the patients by personnel who were kept ignorant
of their nature.
Clinical conduct of the presurgical period
The routine anaesthetist was responsible for anaesthesia but was
accompanied by an observer (likewise an anaesthetist) who
maintained a parallel, independent, anaesthetic record that
included the responses of the anaesthetist to clinical events. Blood
samples for histamine measurement were taken and processed by
two technicians.
The scheme for the presurgical part of the study is shown in
figure 1. The patients arrived in the operating theatre an hour or so
after oral premedication with benzodiazepines and whatever other
medication (antithrombotic, antihypertensive, &c) had been
prescribed. This was carefully recorded. Two peripheral venous
cannulae (one for giving drugs and fluids, the other in the opposite
arm for sampling) were inserted half an hour before the start of the
anaesthetic induction sequence. Next, the antihistamine
prophylaxis or placebo was infused over 3-5 min. It consisted of
F" Figure 1: Protocol. Sampling 
for histamine
Anti H,H,=dimetindene maleate+cimetidine. Shaded bars=parts of routine anaesthesia and preparation for surgery which were influenced by the
controlled trial.
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Table 2: Actions of the responsible anaesthetist
either an ampoule each of dimetindene maleate (4 mg) and
cimetidine (200 mg) or two ampoules of placebo for each 45 kg of
body weight, made up in 100 mL 0-9% NaCl solution. The dose
corresponded to 0’ 1 mg/kg dimetindene and 5 mg/kg cimetidine. It
was added to an infusion of 500 mL Ringer solution which was
started just before.
Anaesthesia was induced 10-15 min later (starting at time zero,
figure 1) by a standardised sequence of drugs consisting of a
pre-curarising dose of alcuronium 0-03 mg/kg (as prophylaxis
against fasciculations), fentanyl 2-5 pg/kg, thiopentone 4-6 mg/kg,
suxamethonium 1 -5 mg/kg, and, after intubation of the trachea and
introduction of N2&ucirc;j&ucirc;2 and enflurane, a fully relaxing dose of
alcuronium 0- 1 mg/kg. The drugs were given at intervals of 1-3 min
(figure 1), to allow time to take 8 mL samples of blood between the
drug applications (to identify any histamine release).7,lo The last
sample of the induction period was 3 min19 after the full dose of
alcuronium, and the next 20 min was designated the postinduction
period.
During this time, the circulation was volume-loaded with 500
mL of either Ringer or Haemaccel-35, randomly allocated. The
volume expanders were contained in an opaque silvered container
and giving-set. During the volume loading, any other necessary
preparations for surgery were carried out, including positioning on
the operating table. Just before the start of surgery, prophylactic
antibiotics (usually cefuroxime and metronidazole) were given to
about half of the patients.
The anaesthetist responsible for the case undertook the routine
monitoring for anaesthesia, including electrocardiogram for
arrhythmias and ST depression, automated noninvasive blood
pressure monitoring (Dinamap), breathing rate, expired tidal and
minute volumes and airway pressures (Drager), and pulse oximetry
(Criticon) as well as the normal clinical observations for cutaneous
signs (erythema, wheals, and oedema) and bronchospasm. The
observer kept a parallel record not only of the observations but also
of the responses of the anaesthetist in terms of the items listed in
table 2. Before the start of surgery, the observer-anaesthetist was
asked in the protocol to guess the treatment group to which the
patient had been allocated. This was to assess the effectiveness or
otherwise of the blinding to treatment in each of the groups.
Assessing clinical events and interventions
The observers’ records were compared with predetermined
endpointsl7,20-22 by scrutineers who were kept ignorant of the
treatment group. Cardiorespiratory disturbances with or without
cutaneous signs, respiratory difficulty, bronchospasm, or cyanosis
were graded as: (1) "detectable" if heart rate changed by more than
10/min or blood pressure changed by more than 10 mm Hg,23 (ii)
"clinically relevant" if they prompted the anaesthetist into one of
the actions listed in table 2, or (iii) "life threatening" if they
prompted emergency measures including unscheduled admission
to an intensive care unit. Tachycardia, bradycardia, and
hypotension were defined as changes in heart rate or blood pressure
rather than as absolute values.
*Assessed by observer-anaesthetist.
tEndocnne, proliferative (eg, Crohn’s disease), or atherosclerotic diseases.
Table 3: Baseline patient characteristics
The scrutineers (one study leader, one observer, one information
technologist) completed the first classification of disturbances
without knowing the contemporaneous plasma histamine
concentrations. These were measured by a standard fluorometric-
fluoroenzymatic assay24 with a detection limit of 0-01 ng/mL. This
was subjected to continual intensive quality control against both
internaP7,24 and external standards.12 An "episode of histamine
release" was defined as a rise of more than three times the
coefficient of variation of the measurement: this amounted to a
200% rise from values between 0-06 and 0-24 ng/mL and a 40% rise
from values greater than 0-24 ng/mL .20 The scrutineers classified
their graded cardiorespiratory disturbances further as "histamine-
related" or "histamine-unrelated", depending on whether they
were found to have coincided with episodes of histamine release.
Reliable and unbiased assessment and designation of the clinical
events was clearly crucial to the interpretation of the study.
Scrupulous attention was paid to this during design, conduct, and
data analysis of the study to ensure: (i) blindness-to-treatment of
the anaesthetists, observers, and scrutineers, (ii) strict adherence to
predetermined criteria2O-23 for classifying the observed
disturbances by the scrutineers, and (iii) double-checking by an
independent advisory group of the scrutineers’ classifications to
assess repeatability (advisory group).
Statistical analysis
The primary objective of the study was to compare the incidence of
histamine-related reactions in the four treatment groups. These
nominal data are presented as percentages with 95% confidence
intervals (CI). Interval variables (plasma histamine) are given as
medians and ranges. Rates of relative risk are calculated by
standard methods. Inferential statistics include chi-square tests
and Kruskal-Wallis nonparametric analysis of variance. Logistic
regression analysis was undertaken to test for interaction of the two
treatment factors in the 2 x 2 factorial design and to allow for
imbalances in risk factors (table 3) additional to the allocated
treatments. The first model included all independent variables,
ASA class assessed by routine anaesthetist
Table 4: Comparison of study sample with clinic population
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NOE 
-
Patient no 42
63 yr, ASA 2, Arterial embolism Time (min)
Figure 2: Postinduction cardiorespiratory disturbances related to histamine in Haemaccel and Ringer group: multiple Interventions
PL= plasma histamine, BP= blood pressure, HR = heart rate.
(a)* = histamine release, vertical dashes=start of postinduction period, vol increased or accelerated volume loading, lenflurane= reduction in
enflurane concentration.
(b)Tph =theophylline, Fen =fenoterol, ES=endotracheal suction, VP= vasopressor. Additional abbreviations in 2a, 2b are explained in figure 1.
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and the second used a stepwise forward selection including
treatment and the set of variables in table 3 with coding of nominal
data as 2/1 for present/absent and Ct=0’2 for entry of a covariate
into the model. The phi-coefficient17 method was used to estimate
the probability that the extent of agreement between the observers’
opinions and the true treatment could have arisen from random
guesswork in each treatment group. The data were analysed with
SAS and Nanostat software on an 486 IBM PC PS/II.
Results
The 240 patients in the study were reasonably
representative of the designated parent population in
several important respects (table 4), despite the exclusion of
patients of American Society of Anesthetists (ASA)
grade> 3 and those with a history of allergy or asthma.
Table 3 gives baseline information on patients in the four
treatment groups. Randomisation was fair -25 chi-square
tests (df= 3) were not significant for any single variable and
forward stepwise logistic regression modelling identified
only malignant disease as a risk factor for clinically relevant
histamine-related disturbances (odds ratio 1-99 after
allowance for treatment differences). 9 patients (4%) did
not complete the study: in 1, anaesthesia was interrupted to
make way for an emergency case; 1 arrived in the induction
room with tachyarrhythmia; in 1 case the observer-
anaesthetist was taken ill; in 2 blood sampling was
impossible; 3 patients were premedicated in error with
promethazine; and 1 patient changed his mind at the last
moment about participating. There was no difference
between treatment groups in the proportions of responsible
(scheduled) anaesthetists (n = 59) or observers (n = 4) of
different seniority and experience. Blindness was not
uniformly achieved across the groups, but fortunately there
were no significant differences with regard to interventions
in the most important groups (clinical relevance)-for
placebo vs anti-H1Hz prophylaxis in all four groups
(phi-coefficient 2-2%) and for volume loading in the two
Haemaccel groups (11 .6 %). The observer-anaesthetists did
identify Ringer solution significantly more often than
expected by chance (36-5%, chi-square p<0’001),
presumably because blood pressure responded less
promptly to Ringer than to Haemaccel.
Histamine-related cardiorespiratory disturbances
occurred with remarkably low plasma histamine levels.
Figure 2 illustrates events in 2 patients who received no
antihistamine prophylaxis. In patient 147 no histamine
release was detectable by our predetermined criteria until
20 min after the start of volume loading with Haemaccel.
Although induction of anaesthesia had itself caused
hypotension that prompted a reduction in enflurane
concentration, the hypotension persisted despite the
volume loading and six other interventions. The maximum
rise in histamine concentration was only 1-3 ng/mL. In
patient 42 there was a small histamine rise after the
pre-curarising alcuronium and another after thiopentone.
The associated clinical events required 7 interventions by
the anaesthetist to deal with hypotension and
bronchospasm. The histamine concentrations fell rapidly
(as expected from its pharmacokinetics23) but rose again
soon after the start of the Ringer infusion, with
accompanying bronchospasm; six further corrective
interventions were required. Again the maximum increase
in histamine concentration was modest.
Episodes of histamine release accompanied between 13
and 16% of the administrations of each drug in the
induction sequence, and occurred during 30% of the
Figure 3: Histamine release in all individual patients after
Haemaccel without antihistamines
Arrows indicate patients with cardiorespiratory disturbances related to
histamine (all grades of severity).
periods of volume loading. In more than one-third of the
patients there were multiple episodes, up to a maximum of
four. The plasma histamine increases from baseline in the
patients receiving placebo-Ringer ranged between 0 and
11-34 ng/mL, median 0-08; in those receiving placebo-
Haemaccel the range was 0 to 63-9 ng/mL, median 0-22. In
those receiving antihistamines and Ringer the
corresponding range was 0-10-66 ng/mL, median 0-04, and
in those receiving antihistamines and Haemaccel it was
0-3-38 ng/mL, median 0-08. The reduction of histamine
release by 50% (Ringer) and 75% (Haemaccel) with the
antihistamines was significant by Kruskal-Wallis testing
(p < 0-001). Figure 3 ranks the maximum increases in
plasma histamine concentration from baseline in the
*&khgr;2=30, df=3, p< 0 0001; tx2= 24, df=3, p< 0001
Table 5: Histamine-related and histamine-unrelated
cardiorespiratory disturbances after induction of anaesthesia
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placebo-Haemaccel group and confirms that detectable
clinical disturbances could accompany very small increases.
However, when the results of the two placebo groups were
pooled, the incidence of histamine-related disturbances of
all degrees of severity was 12% with increases in plasma
histamine of 0-1 ng/mL, 60% with increases of 1-1-2
ng/mL, and 83% with increases greater than 2 ng/mL
(p < 0-0001, df= 2, chi-square). Hence, the severity of
reactions bore no obvious relation to the change in plasma
histamine concentration, though the likelihood of reactions
did.
The numbers of cardiorespiratory disturbances, their
severity, and their attributions are shown in table 5. The
rapid sequence of drug administrations during induction of
anaesthesia sometimes made attribution of clinical
disturbances uncertain, but it was reliable in the post-
induction period. The most striking effect of the
antihistamines was the reduction from 26% (CI 146-374)
to 0% in the incidence of clinically relevant reactions in
those who received Haemaccel. Logistic regression analysis
showed no sign of interaction (chi-square =034, df = 1,
p<0’5). The effects of Haemaccel vs Ringer (odds
ratio= 5-85 [95% CI 228-1502]) and of antihistamines vs
placebo (odds ratio=3 12 [1 34-7-28]) were both highly
significant. The two treatment factors were additive on the
logit scale and the treatment effect of antihistamines was
the same in the Ringer as in the Haemaccel group. In sharp
contrast, there were no significant differences between
treatment groups in the incidence of histamine-unrelated
disturbances of any severity.
The 4 patients who had life-threatening disturbances-
all in the placebo-Haemaccel group-deserve special
mention. The first, aged 75, ASA 3 with gastric cancer,
became flushed, severely hypotensive (40 mm Hg), and
bradycardic (48/min) 10 min after the start of the
Haemaccel infusion and needed emergency treatment
(oxygen, fluids, adrenaline, steroids and antihistamines),
cancellation of the operation, and 4 days in the intensive
care unit. The maximum plasma histamine concentration
was 64 ng/mL. The second, aged 51, ASA 2, with pancreatic
cancer, behaved similarly to the first patient but spent only
1 day in intensive care, having had a maximum rise in
histamine of 13-1 ng/mL. The third patient, aged 68, ASA
3, undergoing reversal of colostomy for non-malignant
disease, required a vasopressor for hypotension and
atropine for bradycardia during the Haemaccel infusion,
after which two wheals and slight angio-oedema were
observed. He had two severe episodes of unexplained
hypotension and further haemodynamic instability during
the 4 hours of operation and was found to have generalised
urticaria at the end. He required emergency treatment and a
day of intensive care. The plasma histamine rose from 0-25
ng/mL by a maximum of only 0-20 ng/mL in the period of
measurement. The fourth patient, aged 52, ASA 2 with
oesophageal cancer, died on the operating table from
ventricular fibrillation after repeated and persistent
hypotension, resistant to fluid resuscitation and
vasopressors and complicated by considerable blood loss.
The maximum plasma histamine concentration was 115
ng/mL 5 min after the start of the Haemaccel infusion.
Several features of the untoward reactions were different
from conventional descriptions and expectations
("anaphylactoid reactions").1-6 Firstly, the severity of the
reactions to Haemaccel in the post-induction period was in
striking contrast to the less alarming reactions documented
for Haemaccel in unanaesthetised patients. 15,16,23 Secondly,
&khgr;2-test,df=1. *p<0 05, tp<0 01.
Table 6: Histamine-related cardiorespiratory disturbances after
Induction of anaesthesia : subgroup analysis
the histamine release and the associated clinical
disturbances were not necessarily immediate, occurring 20
min after the start of volume loading in 11 of the 18
detectable reactions to Haemaccel. In half of the remainder,
rises earlier than 20 min were attributable to a carry-over
effect from the curarising dose of alcuronium. Thirdly,
though haemodynamic instabilities were the most
consistent markers of untoward events, there was no
characteristic direction of change: however, bradycardia
(39%) was more common than tachycardia (17%), and
hypotension (50%) was more common than hypertension
(12%). The hypotensive affects attributable to histamine
release were, of course, partly counteracted by the volume
expansion: as one would expect, this tended to be more
effective with Haemaccel than with Ringer, and was most
effective when Haemaccel was given after antihistamine
prophylaxis had attenuated the effects of any histamine
"release. Fourthly, cutaneous reactions were seen in only 5
patients, and bronchospasm was seen in only 1.
Three findings demanded a cautious subgroup analysis
(table 6)-the selection of malignant disease in logistic
regression modelling; the imbalances of cardiovascular risk
between the treatment groups (table 3); and the effects of
antihistamines on histamine release, confounding their
actions on histamine receptors. Patients with malignant
disease seemed to be at twice the risk for clinically relevant
histamine-related disturbances (RR 1-97 [0-9-4-3]) and at
seven times the risk for life threatening ones (RR 7 23
[0.78-67’1]). Patients with cardiac and/or vascular disease
showed only a slightly increased risk. The effects of the
anti-H1H2 prophylaxis, however, were even stronger in the
two subgroups than in the generality of patients in the
study. Finally, anti-H1H2 reduced the incidence within
each concentration band of histamine, thus demonstrating
receptor-blocking effects after histamine release (table 6).
Discussion
Histamine release was very common during the whole
preoperative period in circumstances that were carefully
selected to represent everyday anaesthesia and surgery. It
occurred at least once in every ten times that each
anaesthetic drug was given and once in every three
infusions for volume expansion. Clinical effects were
detectable in 1 in 5 of the patients who received no
antihistamines. This frequency contrasts sharply with the
reported incidence of anaphylactoid reactions under
anaesthesia of between 1 in 1000 and 1 in 10 000.1-5 Some
say18 that direct non-immunological histamine release is
largely innocuous and that any histamine detected in
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alarming reactions merely marks the co-release of more
dangerous mediators. These claims must face the counter-
argument that there was only one clinically relevant
histamine-related disturbance in the 115 patients given
antihistamines, compared with 20 clinically relevant or
life-threatening disturbances in the 116 given placebo. The
clear effect of antihistamines in reducing histamine-related
but not histamine-unrelated disturbances also validates the
criteria by which the designations were made.
There are four reasons why such frequent and severe
reactions have not previously been attributed to histamine.
First, they have not been looked for as assiduously, with due
attention to selection of a large and representative sample of
everyday anaesthesia and surgery, to application of a
successful double-blind design, and to the scrupulous
blinded application and double-checking of predetermined
criteria for designating episodes of histamine release and
histamine-related disturbances. Second, the clinical
manifestations of the episodes of histamine release were
quite unlike those expected from the classic descriptions of
allergy. There were almost no cutaneous signs, in contrast
to findings in conscious subjects.23 Though haemodynamic
instability was the most characteristic feature, there was no
characteristic direction for the changes. If histamine had
not been measured, many changes could well have been
passed off as "normal" anaesthetic events and treated in the
"normal" way. However, the occurrence of bradycardia in
nearly half of the clinically detectable effects is a reminder
(a) that bradycardia often accompanies the administration
of atracurium22 (which has histamine-releasing properties),
(b) that co-release of adenosine with histamine from the
ischaemic heart can turn a potential histamine-induced
tachycardia into a bradycardia,26 (c) that histamine is a
potent coronary vasoconstrictor, 13 and (d) that bradycardia
can be a marker of silent myocardial ischaemia.27 The third
reason why severe histamine effects might have escaped
notice is that Haemaccel-35 was developed specifically to be
safer than its predecessor, with less cross-linking material
for producing histamine release.16 It proved safe for
example in the Falklands war28 and in 600 unanaesthetised
patients whom we have studied (in parallel to this study)
during plasmapheresis. However, the delay of histamine
release and its effects is consistent with a non-
immunological mechanism based on slow release and
breakdown of cross-linking material from the gelatine
hydrolysate.26 The severity of the reactions under
anaesthesia and the increased risk in patients with
malignant disease are consistent with evidence that
cytokines29 and exposure to anaesthetic drugs30 can prime
mast cells and basophils to exaggerated release of histamine,
in response not only to IgE but also to non-immunological
triggers. The nature of this putative "pharmacological
sensitisation" is still unclear, but its existence means that
studies of histamine release with individual drugs in
animals and conscious human beings may not be a reliable
guide to their safety when they are given along with other
drugs during anaesthesia and surgery.1-4
It was interesting, although not unexpected 7,22 that the
antihistamines reduced the extent of histamine release as
well as the incidence and severity of histamine-related
disturbances. The effectiveness of dimetindene (H1) and
cimetidine (H2) under the routine surgical conditions of this
trial suggests that, rather than relying on allegedly "safe"
drugs that may in fact be dangerous in certain
combinations, we should consider the benefits of routine
antihistamine prophylaxis.
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Prospective study of endogenous tissue plasminogen activator
and risk of stroke
Summary
Few haematological or lipid risk factors have been identified
for stroke, by contrast with coronary heart disease. To find out
whether a marker of endogenous fibrinolytic function might be
associated with stroke risk, we measured tissue plasminogen
activator (tPA) antigen concentrations in baseline plasma
samples from 88 healthy participants in the Physicians’
Health Study who subsequently had first-ever strokes (71
thromboembolic,12 haemorrhagic, 5 indeterminate) and from
471 participants who remained free of cardiovascular disease
during 5 years of follow-up (controls).
Mean baseline tPA concentrations were significantly higher
among men who later had strokes than in the controls (11 14
[SE 0&middot;80] vs 9&middot;59 [0&middot;27] ng/mL, p=0 03). The difference
was largely due to an excess of abnormally high values among
stroke cases. The age-adjusted relative risk for stroke among
men with baseline tPA concentrations above the 95th
percentile of the control distribution was 3 51 (95% Cl
1 72-7&middot;17, p=0 0006) for total stroke and 3 89 (1&middot;83-
8 26, p = 0 0004) for thromboembolic stroke. These findings
did not change substantially in analyses that also controlled
for stroke risk factors (high blood pressure, body-mass index,
smoking, presence of diabetes, and parental history of
myocardial infarction) or the plasma lipid profile.
This prospective study shows that high concentrations of
tPA antigen among apparently healthy men are independently
associated with high risks of future stroke, especially
thromboembolic stroke. This finding is consistent with the
hypothesis that activation of the endogenous fibrinolytic
system occurs years in advance of arterial vascular occlusion.
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Introduction
In most developed countries, stroke is the third commonest
cause of death in adults, following coronary heart disease
and cancer. However, by contrast with coronary heart
disease, few important risk factors have been established for
stroke; the exceptions are age, smoking, and high blood
pressure. Lipid markers that are important in assessment of
coronary risk have been far less reliable for identifying
individuals at risk of stroke, even strokes of
thromboembolic origin.
We have reported that in prospectively collected blood
samples, high concentrations of endogenous tissue-type
plasminogen activator (tPA), the primary mediator of
intravascular fibrinolysis, among apparently healthy men
are strongly associated with the risk of future myocardial
fhfarction.1 On the basis of this finding, we have postulated
that activation of the endogenous fibrinolytic system occurs
several years before vascular occlusion and that the extent
of this activation may serve as a marker for preclinical
atherosclerosis. With cross-sectional data, others have
found that tPA antigen concentrations correlate with
carotid atherosclerosis;2 this observation raises the
possibility that tPA antigen may also be a marker for risk of
stroke. To test this hypothesis prospectively, we assessed
whether high concentrations of tPA antigen among
apparently healthy men are associated with the future
occurrence of stroke.
Patients and methods
In this nested case-control study we analysed blood samples
collected at baseline in the Physicians’ Health Study, a randomised,
double-blind, placebo-controlled trial of aspirin and &bgr;-carotene in
the primary prevention of cardiovascular disease and cancer among
22 071 US male physicians aged 40-84 years, who had not
previously had myocardial infarction, stroke, transient ischaemic
attack, or cancer.3 Before randomisation potentially eligible
physicians were assigned to a regimen of active aspirin and
&bgr;-carotene placebo in an 18-week run-in to identify good compilers
for long-term follow-up. During the run-in period, between 1982
and 1984, 68 &deg;/o of the participants (14 916 men) submitted plasma
samples, which were stored at - 80&deg;C. Annual questionnaires on
risk factors and disease outcomes have been mailed to and returned
by these physicians or their families with a follow-up rate of 99-7%
for morbidity and 100&deg;/o for mortality.
Hospital records were requested for all reported cases of fatal and
non-fatal stroke that occurred after randomisation. These records
